Forum for Science, Industry and Business

Sponsored by:     3M 
Search our Site:

 

Sussex scientist makes MRSA treatment breakthrough with synthetic antibiotic

22.02.2005


A groundbreaking new treatment to combat the hospital killer bug MRSA, which is estimated to cause up to 5,000 deaths a year in Britain, is being developed by a University of Sussex scientist.



Philip Parsons, a professor of organic chemistry, has devised a simple "one-pot" method to make a synthetic version of a natural antibiotic, lactonamycin, which could be used to treat infected patients. He has now received a £280,000 grant from the Engineering and Physical Sciences Research Council towards developing a series of lactonamycin-like substances.

Professor Parsons explains: "The most important thing hospitals can do to fight MRSA is to improve ward cleanliness. But we still need new antibiotics to combat the bug when it arises. "We know that lactonamycin, a naturally occurring antibiotic, can kill MRSA. But it is has not been available as a drug therapy, partly due to its novelty and complexity. We are looking at a simple way to synthesise the antibiotic and its compounds, which could also be highly effective in the fight against infection."


The search for new antibiotics active against "super bugs" such as MRSA is of paramount importance because of the increasing problems faced by hospitals in treating drug-resistant bacterial infections. The latest Government figures estimate that up to 100,000 people catch an infection in UK hospitals every year, with the elderly and the very young most at risk of complications and death.

Research has shown that lactonamycin, an extract of the bacteria Streptomyces rishiriensis, is active against MRSA (methicillin-resistant Staphylococcus aureus).

Naturally occurring chemicals, such as lactonamycin, often have complex molecular structures and are difficult to synthesise because the process usually involves many chemical steps. Professor Parsons has discovered a "one-pot" method - known as cascade reaction - during which several reactions take place at once.

"This is a very exciting discovery," adds Professor Parsons. "It will be important not just for producing lactonamycin, but for making other compounds, natural products and drug substances more efficiently."

| alfa
Further information:
http://www.sussex.ac.uk

More articles from Life Sciences:

nachricht Researchers uncover protein-based “cancer signature”
05.12.2016 | Universität Basel

nachricht The Nagoya Protocol Creates Disadvantages for Many Countries when Applied to Microorganisms
05.12.2016 | Leibniz-Institut DSMZ-Deutsche Sammlung von Mikroorganismen und Zellkulturen GmbH

All articles from Life Sciences >>>

The most recent press releases about innovation >>>

Die letzten 5 Focus-News des innovations-reports im Überblick:

Im Focus: Shape matters when light meets atom

Mapping the interaction of a single atom with a single photon may inform design of quantum devices

Have you ever wondered how you see the world? Vision is about photons of light, which are packets of energy, interacting with the atoms or molecules in what...

Im Focus: Novel silicon etching technique crafts 3-D gradient refractive index micro-optics

A multi-institutional research collaboration has created a novel approach for fabricating three-dimensional micro-optics through the shape-defined formation of porous silicon (PSi), with broad impacts in integrated optoelectronics, imaging, and photovoltaics.

Working with colleagues at Stanford and The Dow Chemical Company, researchers at the University of Illinois at Urbana-Champaign fabricated 3-D birefringent...

Im Focus: Quantum Particles Form Droplets

In experiments with magnetic atoms conducted at extremely low temperatures, scientists have demonstrated a unique phase of matter: The atoms form a new type of quantum liquid or quantum droplet state. These so called quantum droplets may preserve their form in absence of external confinement because of quantum effects. The joint team of experimental physicists from Innsbruck and theoretical physicists from Hannover report on their findings in the journal Physical Review X.

“Our Quantum droplets are in the gas phase but they still drop like a rock,” explains experimental physicist Francesca Ferlaino when talking about the...

Im Focus: MADMAX: Max Planck Institute for Physics takes up axion research

The Max Planck Institute for Physics (MPP) is opening up a new research field. A workshop from November 21 - 22, 2016 will mark the start of activities for an innovative axion experiment. Axions are still only purely hypothetical particles. Their detection could solve two fundamental problems in particle physics: What dark matter consists of and why it has not yet been possible to directly observe a CP violation for the strong interaction.

The “MADMAX” project is the MPP’s commitment to axion research. Axions are so far only a theoretical prediction and are difficult to detect: on the one hand,...

Im Focus: Molecules change shape when wet

Broadband rotational spectroscopy unravels structural reshaping of isolated molecules in the gas phase to accommodate water

In two recent publications in the Journal of Chemical Physics and in the Journal of Physical Chemistry Letters, researchers around Melanie Schnell from the Max...

All Focus news of the innovation-report >>>

Anzeige

Anzeige

Event News

ICTM Conference 2017: Production technology for turbomachine manufacturing of the future

16.11.2016 | Event News

Innovation Day Laser Technology – Laser Additive Manufacturing

01.11.2016 | Event News

#IC2S2: When Social Science meets Computer Science - GESIS will host the IC2S2 conference 2017

14.10.2016 | Event News

 
Latest News

High-precision magnetic field sensing

05.12.2016 | Power and Electrical Engineering

Construction of practical quantum computers radically simplified

05.12.2016 | Information Technology

NASA's AIM observes early noctilucent ice clouds over Antarctica

05.12.2016 | Earth Sciences

VideoLinks
B2B-VideoLinks
More VideoLinks >>>